| 词条 | Tarextumab |
| 释义 |
| IUPAC_name = | image = | alt = | caption = | type = mab | drug_name = | mab_type = | source = u | target = Notch 2, Notch 3 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | onset = | elimination_half-life = | excretion = | CAS_number = 1359940-55-8 | ATCvet = | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | C = 6338 | H = 9804 | N = 1700 | O = 1990 | S = 48 | molecular_weight = 143.2 kDa | UNII = 333YMY788E | synonyms = OMP-59R5 }}Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In Jan 2015 the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1] See also
References1. ^1 {{cite web |url=http://www.cancernetwork.com/news/tarextumab-fda-orphan-drug-lung-pancreatic-cancer |title=Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer |year=2015 }} {{pharma-stub}}{{monoclonals for tumors}} 2 : Experimental cancer drugs|Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。